Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.
News & Analysis: Adverum Biotechnologies, Inc.
Here's how they could keep on rocketing higher.
ADVM earnings call for the period ending September 30, 2019.
Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
Even on an up day for the stock market, these companies lost a lot of ground.
The biotech’s gene therapy isn’t helping patients see better.
ADVM earnings call for the period ending June 30, 2019.
Adverum Biotechnologies and Catalyst Pharmaceuticals could both post sizable gains next month.
Two growth stocks putting up great results and another that's out of favor but still delivering -- here's a trio you need to look at right now.
These biotech stocks have at least quadrupled in just over six months this year.